Surrozen, Inc. (SRZNW)South San Francisco, United States | NasdaqCM
0.01 USD
|
Hot Take ↕ | July 11, 2026, 5:40 a.m. EDT
The security is trading at a negligible price of $0.0094 against a negative book value of -$19.21, indicating severe insolvency where liabilities vastly exceed assets. Fundamentals are catastrophic: the company reports negative earnings per share of -$5.70, negative operating margins of -209%, and massive free cash flow outflows of -$26 million, signaling active consumption of capital without revenue generation. Despite a current ratio of 11.9, this liquidity is illusory given the negative equity and burning cash pile. There is no dividend history to provide income, and the lack of price history prevents any assessment of long-term trajectory. The statistical forecast suggests a minor 1.57% upside over 45 days, but this is irrelevant noise for a company with no viable business model or solvency. Avoid entirely. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.000210 |
| MSTL | 0.001698 |
| AutoARIMA | 0.009400 |
| AutoTheta | 0.021367 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 52% |
| H-stat | 1.55 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 5.82 |
| Attribute | Value |
|---|---|
| Revenue per Share | 0.805 |
| Beta | 0.51 |
| Previous Name | Consonance-HFW Acquisition Corp. |
| Website | https://www.surrozen.com |
| Attribute | Value |
|---|---|
| Address1 | 171 Oyster Point Boulevard |
| Address2 | Suite 400 |
| Ask | 0.0 |
| Ask Size | 0 |
| Beta | 0.508 |
| Bid | 0.0 |
| Bid Size | 0 |
| Book Value | -24.208 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.0094 |
| Current Ratio | 11.913 |
| Custom Price Alert Confidence | HIGH |
| Day High | 0.0099 |
| Day Low | 0.0093 |
| Display Name | Surrozen |
| Ebitda | -42,689,000 |
| Ebitda Margins | 0.0 |
| Eps Trailing Twelve Months | -5.695 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Two Week High | 0.0099 |
| Fifty Two Week High Change | -0.0005000001 |
| Fifty Two Week High Change Percent | -0.05050506 |
| Fifty Two Week Low | 0.0093 |
| Fifty Two Week Low Change | 0.00009999983 |
| Fifty Two Week Low Change Percent | 0.01075267 |
| Fifty Two Week Range | 0.0093 - 0.0099 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,783,690,200,000 |
| Float Shares | 5,092,077 |
| Free Cashflow | -26,107,124 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 44 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -24,641,000 |
| Has Pre Post Market Data | 1 |
| Industry | |
| Industry Key | |
| Ipo Expected Date | 2,021-08-12 |
| Language | en-US |
| Long Business Summary | Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of patients with idiopathic pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California. |
| Long Name | Surrozen, Inc. |
| Market | us_market |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_401948183 |
| Name Change Date | 2,026-07-13 |
| Net Income To Common | -342,560,992 |
| Open | 0.009 |
| Operating Cashflow | -33,460,000 |
| Operating Margins | -2.0911999 |
| Phone | 650 489 9000 |
| Prev Name | Consonance-HFW Acquisition Corp. |
| Previous Close | 0.0094 |
| Price Hint | 4 |
| Price To Book | -0.00038830139 |
| Profit Margins | 0.0 |
| Quick Ratio | 11.7 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 0.0099 |
| Regular Market Day Low | 0.0093 |
| Regular Market Day Range | 0.0093 - 0.0099 |
| Regular Market Open | 0.009 |
| Regular Market Previous Close | 0.0094 |
| Regular Market Price | 0.0094 |
| Regular Market Time | 1,783,713,054 |
| Regular Market Volume | 5,368 |
| Return On Assets | -0.22819 |
| Revenue Growth | 4.086 |
| Revenue Per Share | 0.805 |
| Sand P52 Week Change | 0.20847368 |
| Sector | |
| Sector Key | |
| Short Name | Surrozen, Inc. Warrant |
| Source Interval | 15 |
| State | CA |
| Symbol | SRZNW |
| Total Cash | 106,910,000 |
| Total Cash Per Share | 9.208 |
| Total Debt | 6,778,000 |
| Total Revenue | 7,494,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -5.695 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Type Disp | Equity |
| Volume | 5,368 |
| Website | https://www.surrozen.com |
| Zip | 94,080 |